Bayer Aktiengesellschaft

The Broad Institute, Inc.

Guzman Sanchez

Pierre Wasnaire

Yolanda Cancho Grande

Dmitry Zubov

Sarah Anna Liesa Johannes

Damian Brockschnieder

Till Freudenberger

Kristin Beyer

Dzianis Menshykau

Bryan Macdonald

Yi Xing

Tanja Krainz

Nadine Elowe

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. Ris hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; Ris hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R, R, R, R, Rand Rare independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R, R, Ris H; X, X, X, X, Xand Xare independently N or C; with the proviso that in each ring maximal one X is N.

Substituted hydantoinamides as ADAMTS7 antagonists

Growing community of inventors

Murcia, Spain

Guzman Sanchez